Building the future of medicine
How Canada is accelerating life sciences innovation through collaboration and capital

When BioNTech developed an effective mRNA molecule to fight Covid-19, it still faced a critical challenge: how to deliver the fragile genetic material safely into human cells.
The solution emerged through an in-person introduction at an industry event, where BioNTech’s co-founder, Uğur Şahin, met the founders of Vancouver-based Acuitas Therapeutics. The company had been developing lipid nanoparticle (LNP) systems—microscopic balls of fat, each 700 times smaller than the width of a human hair—that could transport fragile genetic material into human cells. Their partnership would help enable the world’s first authorised Covid-19 vaccine and mark a turning point in the global pandemic.
Such collaboration is characteristic of Canada’s life sciences sector. All across the country, investor conferences and industry gatherings bring together life sciences leaders under one roof. BIOTECanada in Ottawa is an association representing the country’s more than 250 biotech companies and helps convene conferences that foster collaboration and accelerate the development of new treatments.
With increasing venture capital and government support, Canadian life sciences firms are advancing research in areas such as gene therapy and regenerative medicine. These areas were already the focus of most of the country’s pharmaceutical research, but increased funding is accelerating progress.
STEM talent
The strength of Canadian STEM talent has been supported by government support with policies designed to fast-track immigration for highly skilled workers and increase quotas for permanent residency.
Government funding helped to build a biomanufacturing campus at McMaster University in Ontario, while over in Quebec, millions of Canadian dollars were invested in a world-leading, plant-based vaccine development facility.
The country’s manufacturing capabilities are strengthened by investment in underlying innovation. More than C$2.2 billion has been invested in a biomedical research fund that also supports company creation, scale-up and training. New research facilities and start-up accelerators have turned Halifax, Quebec City, Montréal, Ottawa, and Toronto into important life sciences hubs. Each of these cities is a part of a growing global market for life sciences innovation.